Objective To evaluate the clinical value of cardiac MRI for the diagnosis of viral myocarditis (VMC). Methods Such databases as PubMed (1950 to 2009), EMbase (1974 to 2009), and The Cochrane Library (December 2009) were searched to include clinical research reports of diagnosing viral myocarditis with MRI. QUADAS items were used to evaluate the quality of the included studies. The Meta-disc software was used to conduct merger analyses on sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio. The Heterogeneity test was performed and summary receiver operating characteristic curve (SROC) was completed. Results Five trials were included. The value of merger sensitivity, specificity, and diagnostic odds ratio (DOR) were 0.94, 0.69, 2.76, and 28.11, respectively. The area under of SROC curve (AUC) was 0.871 9. Conclusion The current evidence shows that cardiac MRI has high sensitivity (94%) and moderate specificity (69%) in the diagnosis of viral myocarditis. The positive rate in the viral myocarditis group is 28.11 times as high as that in the non-viral myocarditis group, so Cardiac MRI has good diagnostic values for viral myocarditis.
Drug administration is an extremely important aspect in the design and conduct of randomized controlled trials, which can influence the reliability and quality of the trials’ results. This topic covers issues such as blinding, preparation, packaging, labeling, shipping, dispensing and returning of test articles. Good drug administration procedures should ensure the smooth implementation of large-scale multi-center randomized controlled trials and increase their reliability and usefulness.
Vascular aging is the common pathological basis of chronic diseases such as cardiovascular and cerebrovascular diseases, and its early intervention has important public health significance. The overall regulation theory of preventive treatment of disease in traditional Chinese medicine has significant advantages in the prevention and treatment of vascular aging. However, due to the lack of systematic consensus on diagnosis and treatment, the lack of standardization in syndrome differentiation, treatment and prevention has seriously hindered the standardized clinical application and the construction of collaborative diagnosis and treatment system of traditional Chinese and Western medicine. Based on the current evidence and clinical practice, the multidisciplinary expert team developed and registered the "Expert consensus on diagnosis and treatment of vascular aging with traditional Chinese medicine (2026)" aiming to clarify the standardized formulation path of the expert consensus.